Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma.
Open Access
- 1 December 1996
- Vol. 51 (12) , 1178-1184
- https://doi.org/10.1136/thx.51.12.1178
Abstract
BACKGROUND: Leukotriene (LT) B4 is a potent neutrophil chemoattractant and also stimulates eosinophils in vitro, but its role in asthmatic inflammation is unknown. METHODS: The effect of the novel LTB4 receptor antagonist, LY293111, was examined using allergen challenge as a model for asthmatic inflammation in 12 atopic asthmatic subjects in a double blind placebo controlled crossover trial. Subjects with an established early (EAR) and late asthmatic response (LAR) to allergen at screening received oral LY293111 in a dose of 112 mg three times daily for seven days or placebo before further allergen challenge. Each treatment was separated by a washout period of 28 days. Individuals underwent histamine challenge one hour before and three hours after allergen challenge. Bronchoalveolar lavage (BAL) fluid was obtained at bronchoscopy 24 hours after allergen challenge. RESULTS: There was no difference in baseline lung function, EAR, LAR, or in airway responsiveness to histamine before and after allergen between placebo and LY293111. By contrast, treatment with LY293111 significantly reduced the number of neutrophils in BAL fluid expressed as both absolute cell numbers and percentage cell differential counts: absolute cell counts, median (range) 0.04 (0.02-0.15) x 10(6) after LY293111, 0.09 (0.02-0.43) x 10(6) after placebo; percentage differential cell counts 0.35 (0.1-2.0) after LY293111, 0.80 (0.1-3.6) after placebo (p < 0.05). Eosinophils, macrophages, and lymphocytes in BAL fluid did not differ between treatments. There was a significant reduction in the concentration of myeloperoxidase (MPO) with both placebo (16 (6.6) ng/ml) and LY293111 (3.5 (1.8) ng/ml) and of LTB4 (placebo 4.6 (1.2) pg/ml, LY293111 2.2 (0.2) pg/ml). Concentrations of LTC4 and interleukin 8 were reduced, although not significantly, whereas concentrations of interleukin 6, GM-CSF, and TNF-alpha were unchanged by LY293111. CONCLUSIONS: These results demonstrate an influence of LTB4 on neutrophil influx and activation in the airway following allergen challenge. Despite this anti-inflammatory effect, there was no measured physiological benefit and this questions the functional role of the neutrophil in the pathophysiology of allergen induced asthma.Keywords
This publication has 26 references indexed in Scilit:
- Blockade of human neutrophil activation by 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]phenoxy]benzoic acid (LY293111), a novel leukotriene B4 receptor antagonistBiochemical Pharmacology, 1995
- Inflammatory cells and eicosanoid mediators in subjects with late asthmatic responses and increases in airway responsivenessJournal of Allergy and Clinical Immunology, 1992
- Cytokines in symptomatic asthma airwaysJournal of Allergy and Clinical Immunology, 1992
- Leukotriene B4 in the immune systemInternational Journal of Immunopharmacology, 1992
- Leukotrienes and Other Products of the 5-Lipoxygenase PathwayNew England Journal of Medicine, 1990
- Late asthmatic responsesRespiratory Medicine, 1990
- Effects of leukotriene B4 in the human lung. Recruitment of neutrophils into the alveolar spaces without a change in protein permeability.Journal of Clinical Investigation, 1989
- Leukotrienes, LTC and LTB, in bronchoalveolar lavage in bronchial asthma and other respiratory diseasesJournal of Allergy and Clinical Immunology, 1989
- Cellular and protein changes in bronchial lavage fluid after late asthmatic reation in patients with red cedar asthmaJournal of Allergy and Clinical Immunology, 1987
- Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytesNature, 1980